Last reviewed · How we verify
NCT02462538
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Phase 1, PHASE2 trial testing Brentuximab vedotin in ALK+ Anaplastic Large Cell Lymphoma in 3 participants. Terminated before completion.
3 November 2021
Quick facts
| Lead sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 3 November 2015 |
| Primary completion | 3 November 2021 |
| Estimated completion | 3 November 2021 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Brentuximab vedotin — full drug profile →
- Imatinib — full drug profile →
Conditions studied
- ALK+ Anaplastic Large Cell Lymphoma — all drugs for ALK+ Anaplastic Large Cell Lymphoma →
Sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie — full company profile →
Who can join
18 and older, any sex, with ALK+ Anaplastic Large Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open label pilot study of combining BV in a licensed indication with imatinib in patients with ALCL. It is intended as a "window of opportunity" trial in which the study drugs will be given as an initial substitute for conventional chemotherapy with the intention to achieve a remission enabling the patients to proceed to autologous or allogeneic stem cell transplantation, if eligible.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
Tsuyama N, Sakamoto K, Sakata S, Dobashi A, et al · · 2017 · cited 79× · PMID 29279550 · DOI 10.3960/jslrt.17023 -
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.
Prokoph N, Larose H, Lim MS, Burke GAA, et al · · 2018 · cited 58× · PMID 29601554 · DOI 10.3390/cancers10040099 -
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Berger GK, McBride A, Lawson S, Royball K, et al · · 2017 · cited 58× · PMID 28010897 · DOI 10.1016/j.critrevonc.2016.11.009 -
Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.
Begalli F, Bennett J, Capece D, Verzella D, et al · · 2017 · cited 51× · PMID 28829404 · DOI 10.3390/biomedicines5030050 -
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233 -
Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management.
Bennani-Baiti N, Ansell S, Feldman AL. · · 2016 · cited 15× · PMID 26581318 · DOI 10.1586/17474086.2016.1122514 -
Anaplastic lymphoma kinase-special immunity and immunotherapy.
Guo Y, Guo H, Zhang Y, Cui J. · · 2022 · cited 4× · PMID 35958559 · DOI 10.3389/fimmu.2022.908894
Verify or expand the search:
- PubMed search for NCT02462538
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Brentuximab vedotin
Trials testing the same drug.
- NCT05149768 — Open Label Extension Study of Brentuximab Vedotin in Early dcSSc · Phase 2 · recruiting
- NCT05922904 — PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lym · Phase 2 · active not recruiting
- NCT05313243 — Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma · Phase 2 · recruiting
- NCT05414500 — Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides · Phase 1 · recruiting
- NCT05442554 — A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma · Phase 4 · completed
Other Arbeitsgemeinschaft medikamentoese Tumortherapie trials
Trials by the same sponsor.
- NCT06294652 — AGMT Austrian Lymphoma Registry · recruiting
- NCT06250465 — AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry · recruiting
- NCT03984214 — Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Panc · Phase 3 · completed
- NCT03792763 — Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients · Phase 2 · completed
- NCT03301493 — Genomic Testing and Resulting Medical Decisions · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02462538 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arbeitsgemeinschaft medikamentoese Tumortherapie
- Last refreshed: 3 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02462538.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing